Precigen (NASDAQ:PGEN) Announces Earnings Results

Precigen (NASDAQ:PGEN) released its quarterly earnings data on Wednesday. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02, FiscalAI reports. Precigen had a net margin of 15.55% and a return on equity of 86.42%. The company had revenue of $74.15 million during the quarter, compared to the consensus estimate of $71.55 million. During the same period in the previous year, the firm earned ($1.06) earnings per share. Precigen’s revenue for the quarter was up 2437.6% on a year-over-year basis.

Here are the key takeaways from Precigen’s conference call:

• PAPZIMEOS continued its rapid commercial ramp: Q3 net product revenue was $72.9 million, up about 37% from Q2, with more than 500 patients having started treatment and coverage spanning over 315 million U.S. lives.
• Precigen reached profitability and positive operating cash flow: The company reported Q3 net income of $35.8 million and $11.9 million in cash from operations, ahead of its prior cash-flow timeline; it ended the quarter with $51 million in cash and investments plus $96.5 million in receivables.
• Competition is approaching in the RRP market. Management said it anticipated a new entrant and believes PAPZIMEOS’s efficacy, safety, durability, and established commercial network position it favorably, but the competitor’s launch could challenge its market leadership.
• Precigen is pursuing growth beyond the current U.S. adult indication: The EMA is reviewing its PAPZIMEOS application, a redosing study is enrolling with data expected in 2028, and the FDA’s Platform Technology Designation may help advance the AdenoVerse pipeline, including PRGN-2009.

Precigen Stock Performance

PGEN traded up $0.04 on Friday, hitting $4.25. 4,670,449 shares of the company’s stock were exchanged, compared to its average volume of 4,943,383. The firm has a market cap of $1.52 billion, a PE ratio of 42.64 and a beta of 1.01. Precigen has a twelve month low of $3.04 and a twelve month high of $8.98. The stock has a fifty day moving average of $7.03 and a two-hundred day moving average of $5.28. The company has a current ratio of 4.58, a quick ratio of 3.89 and a debt-to-equity ratio of 2.15.

Key Stories Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Q3 revenue was $74.1 million, above the cited $71.5 million estimate, while PAPZIMEOS net revenue rose 37% sequentially to $72.9 million. Precigen also reported $35.8 million in net income and positive cash flow a quarter ahead of its guidance. The company said the FDA granted its AdenoVerse platform Technology Designation, and reported long-term follow-up data showing durable responses after PAPZIMEOS treatment. Read More.
• Positive Sentiment: HC Wainwright raised its EPS forecasts for Q4 2026 and each quarter of 2027, while maintaining a Buy rating and an $18 price target. Citizens JMP also raised its target to $12 from $11 and kept a Market Outperform rating. Higher forecasts and targets may support investor optimism about commercial growth and profitability. Read More.
• Neutral Sentiment: Q3 EPS was $0.08, but reports cited different benchmarks: it exceeded a $0.06 estimate while falling short of Zacks’ $0.09 consensus. The differing comparisons make the earnings-per-share headline less uniformly positive than the revenue and cash-flow results suggest. Read More.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. B. Riley Financial started coverage on shares of Precigen in a research report on Friday, September 25th. They set a “buy” rating and a $12.00 price target for the company. HC Wainwright increased their target price on Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Citigroup reiterated a “market outperform” rating on shares of Precigen in a report on Thursday. Zacks Research lowered Precigen from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Raymond James Financial set a $12.00 price target on Precigen in a report on Thursday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $13.50.

Insider Activity at Precigen

In related news, COO Rutul R. Shah sold 34,658 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $7.50, for a total value of $259,935.00. Following the sale, the chief operating officer owned 465,012 shares of the company’s stock, valued at approximately $3,487,590. This trade represents a 6.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey B. Kindler sold 185,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $7.44, for a total value of $1,376,400.00. Following the transaction, the director owned 17,100 shares of the company’s stock, valued at $127,224. This represents a 91.54% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 235,000 shares of company stock valued at $1,751,400 over the last ninety days. Corporate insiders own 41.40% of the company’s stock.

Precigen Company Profile

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.